Prevalence of cardiovascular drug-related adverse drug reactions consultations in UK primary care: A cross-sectional study
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0307237 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Widya N Insani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Clinical Pharmacy, Padjadjaran University, Bandung, Indonesia. Hauptthemen laut MEDLINE: Primary Health Care, Drug-Related Side Effects and Adverse Reactions, Cardiovascular Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lembaga Pengelola Dana Pendidikan.
Abstract (Originalsprache)
Background
Adverse drug reactions (ADRs) represent a significant barrier to achieve optimal treatment outcomes. Cardiovascular drugs, including antihypertensive drugs, lipid-lowering drugs, and antithrombotic drugs, are among the most prescribed medications in the primary care setting.
Objectives
To estimate the prevalence of cardiovascular drug-related ADRs consultations in United Kingdom (UK) primary care and identify risk factors of these ADRs.
Methods
This was a cross-sectional study of cardiovascular drug users between 2000–2019 using UK IQVIA Medical Research Data. ADRs consultations were identified using database screening method employing standardised designated codes. The overall and annual age-standardised prevalence was estimated using direct standardisation method using 2019 mid-year UK population. Risk factors of ADRs consultations were estimated using logistic regression model stratified by therapeutic areas.
Results
The standardised prevalence of consultations related to cardiovascular drugs ADRs was 10.60 (95% CI. 10.46, 10.75) per 1000 patients. Patients aged 70–79 years had the highest occurrence of ADRs consultations. The most frequently drug classes implicated in the ADRs consultations were statins (n = 9,993 events, 27.09%), beta-blockers (n = 8,538 events, 23.15%), ACEIs/ARBs (n = 8,345 events, 22.62%), and aspirin (n = 6,482 events, 17.57%). Risk factors of ADRs consultations were previous history of cardiovascular diseases, e.g., myocardial infarction and stroke; advanced age, comorbidities; diabetes and dyslipidaemia; and polypharmacy.
Conclusions
The burden of cardiovascular drug-related ADRs consultations in primary care was considerable. Statins, beta-blockers, ACEIs/ARBs, and aspirin were the most frequently implicated drug classes. Closer clinical monitoring should be performed for patients affected by the ADRs to mitigate the risk of suboptimal treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Clinical Pharmacy, Padjadjaran University, Bandung, Indonesia.
- Research Department of Practice and Policy, School of Pharmacy, University College London, London, United Kingdom.
- Centre of Excellence for Pharmaceutical Care Innovation, Padjadjaran University, Bandung, Indonesia.
- Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
ORCID-Profile: Widya N Insani, Cate Whittlesea
Förderung
- Lembaga Pengelola Dana Pendidikan
Zitieren
APA
Insani, W. N., Whittlesea, C., & Wei, L. (2024). Prevalence of cardiovascular drug-related adverse drug reactions consultations in UK primary care: A cross-sectional study. PLOS ONE. https://doi.org/10.1371/journal.pone.0307237
Vancouver
Insani WN, Whittlesea C, Wei L. Prevalence of cardiovascular drug-related adverse drug reactions consultations in UK primary care: A cross-sectional study. PLOS ONE. 2024. doi:10.1371/journal.pone.0307237
BibTeX
@article{Insani2024,
author = {Insani, Widya N and Whittlesea, Cate and Wei, Li},
title = {Prevalence of cardiovascular drug-related adverse drug reactions consultations in UK primary care: A cross-sectional study},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0307237}
}
EUVIMED